Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Celyad SA
CYADCurrent price
0.25 EUR
-0.008 EUR (-3.10%)
Last closed
0.24 EUR
Company
www.celyad.com
ISIN
BE0974260896
Sector
Healthcare
Industry
Biotechnology
Exchange
Euronext Brussels
Capitalization
9 543 775 EUR
Yield for 12 month
-68.75 %
1Y
3Y
5Y
10Y
15Y
CYAD
Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. Address: Axis Business Park, Mont-Saint-Guibert, Belgium, 1435
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
0.45 EURP/E ratio
–Dividend Yield
–Current Year
+101 282 EUR
Last Year
–
Current Quarter
+57 592 EUR
Last Quarter
+43 690 EUR
Current Year
+882 742 EUR
Last Year
-1 429 863 EUR
Current Quarter
-361 437 EUR
Last Quarter
-394 205 EUR
Key Figures CYAD
1 year
3 years
5 years
10 years
EBITDA
-8 940 615 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-33.03 %
PEG Ratio
–
Return On Equity TTM
-159.08 %
Wall Street Target Price
0.45 EUR
Revenue TTM
101 282 EUR
Book Value
0.15 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
4 965 EUR
Earnings per share
-1.35 EUR
Diluted Eps TTM
-1.35 EUR
Most Recent Quarter
IV 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CYAD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CYAD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation CYAD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
124.5941
Price Sales TTM
94.2298
Enterprise Value EBITDA
-0.32
Price Book MRQ
9.7371
Financials CYAD
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CYAD
For 52 weeks
0.21 EUR
0.92 EUR
50 Day MA
0.25 EUR
Shares Short Prior Month
–
200 Day MA
0.32 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart